Treatment of bronchiolitis: state of the art. (Q38117793)

29 August 2017

title

Treatment of bronchiolitis: state of the art. (English)

1 reference

ORCID Public Data File 2021

29 August 2017

0 references

Eugenio Baraldi

1 reference

Francesco Martinolli

series ordinal

object named as

Francesco Martinolli

1 reference

29 August 2017

Liviana Da Dalt

1 reference

29 August 2017

Silvia Bressan

series ordinal

1 reference

29 August 2017

Giorgio Perilongo

series ordinal

1 reference

29 August 2017

publication date

1 June 2013

1 reference

29 August 2017

published in

Early Human Development

1 reference

29 August 2017

volume

89 Suppl 1

1 reference

29 August 2017

page(s)

S31-6

1 reference

Current therapy for bronchiolitis

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

Respiratory syncytial virus prevention and therapy: Past, present, and future

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

High risk for RSV bronchiolitis in late preterms and selected infants affected by rare disorders: a dilemma of specific prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

Bronchiolitis: recent evidence on diagnosis and management

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

Diagnosis and management of bronchiolitis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

Nebulized hypertonic saline solution for acute bronchiolitis in infants

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

Chest physiotherapy for acute bronchiolitis in paediatric patients between 0 and 24 months old

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

Steam inhalation or humidified oxygen for acute bronchiolitis in children up to three years of age

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

Bronchodilators for bronchiolitis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

Steroids and bronchodilators for acute bronchiolitis in the first two years of life: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

Epinephrine for bronchiolitis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

Glucocorticoids for acute viral bronchiolitis in infants and young children

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

Inhaled corticosteroids during acute bronchiolitis in the prevention of post-bronchiolitic wheezing

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

Nebulised deoxyribonuclease for viral bronchiolitis in children younger than 24 months

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

High flow nasal cannulae therapy in infants with bronchiolitis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

Reduced intubation rates for infants after introduction of high-flow nasal prong oxygen delivery.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

Pilot study of vapotherm oxygen delivery in moderately severe bronchiolitis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

Research in high flow therapy: mechanisms of action.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

High flow nasal cannula therapy as respiratory support in the preterm infant

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

Effects of flow rate and airleak at the nares and mouth opening on positive distending pressure delivery using commercially available high-flow nasal cannula systems: a lung model study

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

Nasopharyngeal airway pressures in bronchiolitis patients treated with high-flow nasal cannula oxygen therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

Humidified high-flow nasal cannula: is it the new and improved CPAP?

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

Use of continuous positive airway pressure (CPAP) in acute viral bronchiolitis: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

Serious air leak syndrome complicating high-flow nasal cannula therapy: a report of 3 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

Bronchiolitis management in pediatric emergency departments in Australia and New Zealand: a PREDICT study.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

Nasogastric hydration versus intravenous hydration for infants with bronchiolitis: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

Hypertonic saline or high volume normal saline for viral bronchiolitis: mechanisms and rationale

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

Is nebulised hypertonic saline useful as an adjunctive treatment for acute bronchiolitis in infants and children less than 24 months of age?

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

Repeated dosing of nebulised 5% saline improves respiratory scores in inpatients with mild to moderate bronchiolitis at 48 h

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

Nebulized hypertonic saline without adjunctive bronchodilators for children with bronchiolitis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

Nebulized 5% or 3% hypertonic or 0.9% saline for treating acute bronchiolitis in infants

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

Epinephrine for acute bronchiolitis, but not steroids alone, reduces hospital admissions

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

Epinephrine and dexamethasone in children with bronchiolitis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

Antibiotics for bronchiolitis in children

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

Clarithromycin in the treatment of RSV bronchiolitis: a double-blind, randomised, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

Azithromycin does not improve disease course in hospitalized infants with respiratory syncytial virus (RSV) lower respiratory tract disease: a randomized equivalence trial

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

Azithromycin therapy in hospitalized infants with acute bronchiolitis is not associated with better clinical outcomes: a randomized, double-blinded, and placebo-controlled clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

Nasal lavage leukotrienes in infants with RSV bronchiolitis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

Montelukast as an episodic modifier for acute viral bronchiolitis: a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

A double-blind, placebo-controlled, randomized trial of montelukast for acute bronchiolitis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

Study of montelukast for the treatment of respiratory symptoms of post-respiratory syncytial virus bronchiolitis in children

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

Montelukast does not prevent reactive airway disease in young children hospitalized for RSV bronchiolitis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

A randomized intervention of montelukast for post-bronchiolitis: effect on eosinophil degranulation

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

Efficacy of recombinant human deoxyribonuclease I in the hospital management of respiratory syncytial virus bronchiolitis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

Recombinant human deoxyribonuclease in infants with respiratory syncytial virus bronchiolitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

Inhaled furosemide in hospitalized infants with viral bronchiolitis: a randomized, double-blind, placebo-controlled pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

Are methylxanthines effective in preventing or reducing apnoeic spells in infants with bronchiolitis?

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

Apnoeas in bronchiolitis: is there a role for caffeine?

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

Incidence of apnea in infants hospitalized with respiratory syncytial virus bronchiolitis: a systematic review.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

The promise, pitfalls and progress of RNA-interference-based antiviral therapy for respiratory viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

Passive immunisation of preterm infants with palivizumab against RSV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

Special populations: do we need evidence from randomized controlled trials to support the need for respiratory syncytial virus prophylaxis?

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

Asthma, allergy and respiratory infections: the vitamin D hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

Cord blood vitamin D deficiency is associated with respiratory syncytial virus bronchiolitis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2813%2970011-2

7 January 2021

10.1016/S0378-3782(13)70011-2

Identifiers

DOI

1 reference

29 August 2017

1 reference